Gerstein, H.C., Yusuf, S., Boxch, J., et al. (2006) DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators: Effect of Rosiglitazone on the Frequency of Diabetes in Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose: A Randomized Controlled Trial. The Lancet, 368, 1096-105.
https://doi.org/10.1016/S0140-6736(06)69420-8

has been cited by the following article:

• TITLE: Evidence in Primary Prevention of Type 2 Diabetes Mellitus—What It Means for Primary Prevention of Type 2 Diabetes Mellitus Epidemic in Papua New Guinea

  AUTHORS: Leslie Bahn Kawa

  KEYWORDS: Primary Prevention, Prevention Trials, Type 2 Diabetes Mellitus, Prediabetes

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.12 No.2, April 29, 2022

  ABSTRACT: Type 2 diabetes is in epidemic proportion in Papua New Guinea. Although many people are at high-risk of developing diabetes, there is no diabetes prevention policy and services in Papua New Guinea to address this problem. A literature search was carried out to assess the available evidence in the primary prevention of type 2 diabetes mellitus among the population with pre-diabetes. The result shows that the primary preventative studies conducted on lifestyle modification and the use of metformin in prediabetes patients reduced overt type 2 diabetes mellitus. The application of the evidence in the prevention of the type 2 diabetes epidemic in Papua New Guinea, driven by a policy is feasible to address the diabetes epidemic.